Work

Reply to: Is the role of eosinophils in refractory chronic cough truly dismissed? Mepolizumab reduced blood and sputum eosinophils, but not eosinophil-derived neurotoxin

Year: 2026

Type: letter

Abstract: Extract Reply to W. Zhan and co-workers: The recently published MUCOSA trial in the European Respiratory Journal, which evaluated the effects of mepolizumab on objective cough frequency in patients with refractory chronic cough (RCC), has prompted a re-evaluation of the role of eosinophils in cough pathophysiology [1].

Source: European Respiratory Journal

DOI: 10.1183/13993003.00143-2026

Authors: Christiane Whetstone, Nermin Diab, Danica Brister, Elena Kum, Mustafaa Wahab, Wafa Hassan, Sue Beaudin, Catie Obminski, Jennifer Wattie, Lesley Wiltshire, Karen Howie, Kieran Killian, Kimberley Holt, Roma Sehmi, Jaclyn A. Smith, Paul M. O'Byrne, Imran Satia, Gail M. Gauvreau

Institutions: McMaster University, McGill University, University of Calgary, University of Manchester, St. Joseph’s Healthcare Hamilton

Language: English

Topic: Respiratory and Cough-Related Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funder: GlaxoSmithKline

OpenAlex ID: W7160501462

Cites: 12

Cited by:

Related to: